OKYO Pharma Limited (OKYO) Stock Forecast
OKYO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $8.33 average of analyst targets
- Upside to target
- +491.0% from the latest close
- Next earnings
- —
- 52-week range
- $1.29 – $3.11
OKYO analyst ratings
3 analystsNumber of analysts at each rating.
OKYO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OKYO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | −$0.04 | −$0.04 | −$0.04 | — | — | 1 |
| Current fiscal year (FY2027) | −$0.12 | −$0.12 | −$0.12 | −$0.21 | +44.1% | 1 |
| Next fiscal year (FY2028) | −$0.66 | −$0.66 | −$0.66 | −$0.12 | −450.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OKYO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (FY2028) | $11.0M | $11.0M | $11.0M | 0.0% | 1 |
OKYO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OKYO revenue: reported and forecast
OKYO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0.00 | −$0.04 | −$0.04 | −$0.04 | −$0.04 | — | 0 up · 0 down |
| Current fiscal year (FY2027) | −$0.20 | −$0.20 | −$0.12 | −$0.12 | −$0.12 | −40.0% | 1 up · 0 down |
| Next fiscal year (FY2028) | −$0.59 | −$0.59 | −$0.66 | −$0.66 | −$0.66 | +11.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OKYO earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; OKYO beat in 5 of 7.
What analysts expect from OKYO
3 analysts cover OKYO Pharma; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.33, 491.0% above the latest close of $1.41. Analysts expect earnings of −$0.12 per share for FY2027, +44.1% from a year earlier. For FY2028 the average estimate is −$0.66 per share on revenue of $11.0 million. OKYO Pharma beat the EPS estimate in 5 of the last 7 quarters.
Related: OKYO income statement, OKYO key metrics, OKYO chart. See the OKYO stock overview for the latest quote and news.
OKYO forecast FAQ
What is OKYO Pharma's price target?
The average analyst price target for OKYO Pharma is $8.33, 491.0% above the latest close of $1.41.
Is OKYO Pharma a buy, hold or sell?
Of 3 analysts covering OKYO Pharma, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is OKYO Pharma's EPS forecast?
Analysts forecast −$0.12 per share for FY2027 (range −$0.12 to −$0.12); for FY2028 the estimate is −$0.66.
Does OKYO Pharma usually beat earnings estimates?
OKYO Pharma reported EPS at or above the analyst estimate in 5 of the last 7 quarters.